Find Approved Dermatology Drugs in Clinical Development

Lead Product(s): Lidocaine,Hyaluronic Acid

Therapeutic Area: Dermatology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Crescita Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Distribution Agreement January 20, 2020

Details:

The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid ART-Filler® injectables range and NCTF® 135 HA.

Lead Product(s): Aprepitant

Therapeutic Area: Dermatology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hoth Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs.

Lead Product(s): Trifarotene

Therapeutic Area: Dermatology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Galderma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 08, 2020

Details:

Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.